Validation of novel imaging methodologies for use as cancer clinical trial end-points.

[1]  M. Okada,et al.  [New response evaluation criteria in solid tumours-revised RECIST guideline (version 1.1)]. , 2009, Gan to kagaku ryoho. Cancer & chemotherapy.

[2]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[3]  S. Paggi,et al.  Sorafenib in Advanced Hepatocellular Carcinoma , 2008 .

[4]  M. Buyse,et al.  Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Christopher D Stave,et al.  Analysis of phase II studies on targeted agents and subsequent phase III trials: what are the predictors for success? , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  E. Eisenhauer,et al.  Review of phase II trial designs used in studies of molecular targeted agents: outcomes and predictors of success in phase III. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Daniel J Sargent,et al.  Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  D. Sargent,et al.  Progression-free survival is a surrogate for survival in advanced colorectal cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  O. Hoekstra,et al.  P84 Response monitoring with positron emission tomography (PET) in patients with advanced non-small-cell lung cancer (NSCLC) treated with bevacizumab and erlotinib: a phase II study , 2007 .

[10]  Daniel J Sargent,et al.  End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Michael L Maitland,et al.  Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer. , 2007, Journal of the National Cancer Institute.

[12]  A. Sorensen,et al.  Imaging Biomarker Applications in Oncology Drug Development , 2007 .

[13]  Haesun Choi,et al.  We should desist using RECIST, at least in GIST. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Mitchell D Schnall,et al.  Dynamic Contrast-Enhanced Magnetic Resonance Imaging for Assessing Tumor Vascularity and Vascular Effects of Targeted Therapies in Renal Cell Carcinoma , 2007, Clinical Cancer Research.

[15]  G. Parker,et al.  DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents , 2007, British Journal of Cancer.

[16]  J. Buckner,et al.  The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme. , 2007, Neuro-oncology.

[17]  C. Jaffe.  Measures of response: RECIST, WHO, and new alternatives. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  W. Weber.  Positron emission tomography as an imaging biomarker. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Joel Karp,et al.  Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[20]  R. Weissleder.  Molecular Imaging in Cancer , 2006, Science.

[21]  W. Richter.  Imaging biomarkers as surrogate endpoints for drug development , 2006, European Journal of Nuclear Medicine and Molecular Imaging.

[22]  S. Larson,et al.  The Progress and Promise of Molecular Imaging Probes in Oncologic Drug Development , 2005, Clinical Cancer Research.

[23]  W. Sauerbrei,et al.  Reporting recommendations for tumor marker prognostic studies (REMARK). , 2005, Journal of the National Cancer Institute.

[24]  Dongsheng Tu,et al.  Objective Responses in Patients with Malignant Melanoma or Renal Cell Cancer in Early Clinical Studies Do Not Predict Regulatory Approval , 2005, Clinical Cancer Research.

[25]  M. Ratain.  Phase II Oncology Trials: Let's Be Positive , 2005, Clinical Cancer Research.

[26]  M. Sormani,et al.  Objective response to chemotherapy as a potential surrogate end point of survival in metastatic breast cancer patients. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  J. Hainsworth,et al.  A randomized, double-blind, placebo-controlled, phase III study in patients (Pts) with metastatic adenocarcinoma of the colon or rectum receiving first-line chemotherapy with oxaliplatin/5-fluorouracil/leucovorin and PTK787/ZK 222584 or placebo (CONFIRM-1) , 2005 .

[28]  Wolfgang A Weber,et al.  Use of PET for monitoring cancer therapy and for predicting outcome. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[29]  Bruce D Cheson,et al.  Progress and Promise of FDG-PET Imaging for Cancer Patient Management and Oncologic Drug Development , 2005, Clinical Cancer Research.

[30]  Paul S Albert,et al.  Assessing surrogates as trial endpoints using mixed models , 2005, Statistics in medicine.

[31]  Daniel J Sargent,et al.  Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  N. Tamaki,et al.  Reduced 123I-BMIPP uptake implies decreased myocardial flow reserve in patients with chronic stable angina , 2005, European Journal of Nuclear Medicine and Molecular Imaging.

[33]  Mark J Ratain,et al.  Phase II studies of modern drugs directed against new targets: if you are fazed, too, then resist RECIST. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  Geert Molenberghs,et al.  The validation of surrogate end points by using data from randomized clinical trials: a case‐study in advanced colorectal cancer , 2004 .

[35]  M. Byrne,et al.  Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[36]  A. D. Van den Abbeele,et al.  Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs). , 2002, European journal of cancer.

[37]  G. Molenberghs,et al.  Validation of surrogate end points in multiple randomized clinical trials with failure time end points , 2001 .

[38]  M. Christian,et al.  [New guidelines to evaluate the response to treatment in solid tumors]. , 2000, Bulletin du cancer.

[39]  Geert Molenberghs,et al.  Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis , 2000, The Lancet.

[40]  K. Herholz,et al.  Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. , 1999, European journal of cancer.

[41]  G. Molenberghs,et al.  Criteria for the validation of surrogate endpoints in randomized experiments. , 1998, Biometrics.

[42]  R. Bast,et al.  Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. , 1996, Journal of the National Cancer Institute.

[43]  D. DeMets,et al.  Surrogate End Points in Clinical Trials: Are We Being Misled? , 1996, Annals of Internal Medicine.

[44]  B. Graubard,et al.  Statistical validation of intermediate endpoints for chronic diseases. , 1992, Statistics in medicine.

[45]  W. Agras,et al.  A Randomized, Double‐Blind, Placebo‐Controlled: Trial of Trazodone Hydrochloride in Chronic Low Back Pain Syndrome , 1990, Journal of clinical psychopharmacology.

[46]  R. Prentice.  Surrogate endpoints in clinical trials: definition and operational criteria. , 1989, Statistics in medicine.